PFE · 8-K · 20260804PR000094
Intangible Asset Impairments
PFIZER INC · 2026-08-04 · Importance 96 · Surprise 100 · In source text
Pfizer reported a second-quarter 2026 loss attributable to common shareholders of $248 million, compared with $2.910 billion of income in the prior-year quarter. The loss included $4.325 billion of intangible asset impairment charges, including $3.8 billion related to in-process R&D assets for sigvotatug vedotin and $525 million related to Oxbryta technology rights. The sigvotatug impairment followed unfavorable Phase 3 results in second-line metastatic non-squamous non-small cell lung cancer. Pfizer determined there was no viable pathway to return Oxbryta to the U.S. market after discussions with the FDA.
Key facts
- Reported Loss Per Share reflects $4.3 billion in Non-Cash Intangible Asset Impairments source
- Components of Q2 2026 intangible asset impairment charges: $3.8 billion IPR&D impairments and $525 million for Oxbryta developed technology rights source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | -25.3% | Components of Q2 2026 intangible asset impairment charges: $3.8 billion IPR&D impairments and $525 million for Oxbryta developed… |
| net_income | negative | realized | -3.5% | Components of Q2 2026 intangible asset impairment charges: $3.8 billion IPR&D impairments and $525 million for Oxbryta developed… |
| assets | negative | realized | — | Components of Q2 2026 intangible asset impairment charges: $3.8 billion IPR&D impairments and $525 million for Oxbryta developed… |
| assets | negative | realized | — | Components of Q2 2026 intangible asset impairment charges: $3.8 billion IPR&D impairments and $525 million for Oxbryta developed… |